Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, vol.50, issue.2, pp.227-269, 2009. ,
Chronic hepatitis B: update, Hepatology, vol.50, issue.3, pp.661-663, 2009. ,
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, Jama, vol.295, issue.1, pp.65-73, 2006. ,
Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, vol.351, issue.15, pp.1521-1552, 2004. ,
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology ,
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterology, vol.131, issue.6, pp.1743-51, 2006. ,
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, vol.351, issue.12, pp.1206-1223, 2004. ,
Peginterferon Alfa-2a, lamivudine, and the combination for ,
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B, Clin Infect Dis, vol.36, issue.6, pp.687-96, 2003. ,
Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, vol.125, issue.6, pp.1714-1736, 2003. ,
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.48, issue.3, pp.750-758, 2008. ,
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B, Gastroenterology, vol.136, issue.2, pp.486-95, 2009. ,
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.51, issue.2, pp.422-452 ,
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, vol.348, issue.4, pp.883-91, 2004. ,
DOI : 10.1002/hep.20381
Evolution of multi-drug resistant hepatitis B virus during sequential therapy, Hepatology, vol.44, issue.3, pp.703-715, 2006. ,
Selection of a multiple drug-resistant hepatitis B virus strain in a liver ,
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient, J Hepatol, vol.46, issue.3, pp.531-539, 2007. ,
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues, J Hepatol, vol.52, issue.4, pp.493-500 ,
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues, Hepatology, vol.48, issue.1, pp.73-80 ,
DOI : 10.1002/hep.23246
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatol Int, vol.2, issue.3, pp.263-83, 2008. ,
Mutation rate of the hepadnavirus genome, Virology, vol.170, issue.2, pp.595-602, 1989. ,
Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen, J Virol, vol.83, issue.4, pp.1718-1744, 2009. ,
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy, Hepatology, vol.34, issue.4, pp.785-91, 2001. ,
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update, Clin Gastroenterol Hepatol, vol.4, issue.8, pp.936-62, 2006. ,
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B, Clin Gastroenterol Hepatol, vol.5, issue.8, pp.890-897, 2007. ,
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response ,
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy, Hepatology, vol.49, issue.5, pp.1503-1517, 2009. ,
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein, Nat Biotechnol, vol.26, issue.3, pp.335-376, 2008. ,